CAH Cardinal Health (CAH) Insider Trading, Ownership & Congress Trades
Wholesale & Retail · Wholesale-drugs, proprietaries & druggists' sundries · CIK 0000721371
Form 144 · 7
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
710
13F, latest reported quarter
What the filings say about CAH
Insiders, 180 days
-$59.6M net sold
7 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: purchase, 2025-10-24
Planned sales (Form 144), 90 days
$59.5M
7 notices
Cardinal Health insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, CARDINAL HEALTH INC insiders sold a net $59.6M of stock across 84 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Aug 18, 2026.
- The trade is 2.7% of the 228,926 shares held after it.
- 6 other insiders sold within 30 days.
- 710 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Hollar Jason M. sold about $1.4M of CAH on Aug 19, 2026; 6 other insiders sold within 30 days and 710 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Aug 18, 2026.
- The trade is 1.5% of the 225,469 shares held after it.
- 6 other insiders sold within 30 days.
- 710 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Hollar Jason M. sold about $809.9K of CAH on Aug 19, 2026; 6 other insiders sold within 30 days and 710 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Aug 18, 2026.
- The trade is 2.6% of the 219,765 shares held after it.
- 6 other insiders sold within 30 days.
- 710 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Hollar Jason M. sold about $1.3M of CAH on Aug 19, 2026; 6 other insiders sold within 30 days and 710 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Aug 18, 2026.
- The trade is 3.2% of the 213,034 shares held after it.
- 6 other insiders sold within 30 days.
- 710 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Hollar Jason M. sold about $1.6M of CAH on Aug 19, 2026; 6 other insiders sold within 30 days and 710 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Aug 18, 2026.
- The trade is 8.2% of the 196,847 shares held after it.
- 6 other insiders sold within 30 days.
- 710 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Hollar Jason M. sold about $3.8M of CAH on Aug 19, 2026; 6 other insiders sold within 30 days and 710 funds added in the latest 13F quarter.84 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$59.6M over 180 days
-$59.6M over 90 days
below 94% of Wholesale & Retail
Congress
no House purchase disclosed in the last 12 months
Funds
710 funds bought in last quarter
more than 94% of Wholesale & Retail
Revenue
+14.2% year over year
more than 81% of Wholesale & Retail
Margin
0.7% net margin
below 55% of Wholesale & Retail
Buybacks
$1.4B repurchased, FY to 2026-06-30
more than 96% of Wholesale & Retail
Short interest
3.2% of the float short (float per yahoo 2026-10-26) · 3.4 days to cover · settled 2026-09-30
more than 53% of Wholesale & Retail
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CAH
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+57.6%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CAH: institutional holders (13F)
13F holdings, latest reported quarter
26,490,633 sh
$6.3B
15,292,186 sh
$3.6B
14,860,271 sh
$3.5B
13,717,894 sh
$3.3B
11,967,121 sh
$2.8B
Congress trades in CAH
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2025-10-24 · disclosed 4 days later
$1,001 - $15,000
Bought 2025-05-14 · disclosed 5 days later
$1,001 - $15,000
Bought 2025-05-05 · disclosed 1 day later
$1,001 - $15,000
Bought 2025-04-08 · disclosed 30 days later
$1,001 - $15,000
Bought 2025-03-17 · disclosed 2 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CAH planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Mary Scherer
Filed 2026-08-19
$546.5K
Aaron Alt
Filed 2026-08-18
$9.9M
Jason Hollar
Filed 2026-08-18
$29.4M
Stephen Mason
Filed 2026-08-18
$8.3M
Jessica Mayer
Filed 2026-08-18
$7.0M
CAH mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Saratoga Health & Biotechnology Fund
$674.8K position · as of 2026-05-31
6.4%
LIVE OAK HEALTH SCIENCES FUND
$3.3M position · as of 2026-07-31
5.9%
Liberty One Defensive Dividend Growth ETF
$3.4M position · as of 2026-07-31
5.6%
ROCK OAK CORE GROWTH FUND
$623.6K position · as of 2026-07-31
4.6%
Nestyield Total Return Guard ETF
$2.3M position · as of 2026-05-31
4.1%
Brown Advisory Sustainable Value ETF
$16.6M position · as of 2026-06-30
4.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Veterans Affairs
RADIOPHARMACEUTICALS · 2022-10-01
$3.9M
Department Of Veterans Affairs
RADIOPHARMACEUTICALS · 2026-10-01
$3.1M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $59.6M sold by insiders over 180 days, 710 funds added last quarter, $59.5M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
CAH financials
Revenue growth
+14.2%
XBRL, annual
Net margin
0.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$244.7B
four quarters, 2025-01-01 to 2025-12-31
Revenue, TTM CAH
| FY Jun 2026 | $244.7B |
| FY Jun 2025 | $222.6B |
| FY Jun 2024 | $226.8B |
| FY Jun 2023 | $205.0B |
| FY Jun 2022 | $181.4B |
| Dec 2025 | $65.6B |
| Sep 2025 | $64.0B |
| Jun 2025 | $60.2B |
| Mar 2025 | $54.9B |
| Dec 2024 | $55.3B |
| Sep 2024 | $52.3B |
| Jun 2024 | $59.7B |
| Mar 2024 | $54.9B |
At each fiscal year end
Single quarter
Net margin, TTM
+0.7%
net income over revenue, 2025-01-01 to 2025-12-31
Net margin, TTM CAH
| FY Jun 2026 | +0.7% |
| FY Jun 2025 | +0.7% |
| FY Jun 2024 | +0.4% |
| FY Jun 2023 | n/a |
| FY Jun 2022 | -0.5% |
| Dec 2025 | +0.7% |
| Sep 2025 | +0.7% |
| Jun 2025 | +0.4% |
| Mar 2025 | +0.9% |
| Dec 2024 | +0.7% |
| Sep 2024 | +0.8% |
| Jun 2024 | +0.4% |
| Mar 2024 | +0.5% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$5.5B
operating cash flow minus capex, 2025-01-01 to 2025-12-31
Free cash flow, TTM CAH
| FY Jun 2026 | $5.5B |
| FY Jun 2025 | $1.9B |
| FY Jun 2024 | $3.3B |
| FY Jun 2023 | $2.4B |
| FY Jun 2022 | $2.8B |
| Dec 2025 | $555.0M |
| Sep 2025 | $865.0M |
| Jun 2025 | $1.3B |
| Mar 2025 | $2.8B |
| Dec 2024 | -$495.0M |
| Sep 2024 | -$1.7B |
| Jun 2024 | $1.9B |
| Mar 2024 | -$139.0M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity CAH
| FY Jun 2026 | n/a |
| FY Jun 2025 | n/a |
| FY Jun 2024 | n/a |
| FY Jun 2023 | n/a |
| FY Jun 2022 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
| Mar 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.73x
TTM operating cash flow over long-term debt only, 2025-12-31
Cash flow to debt CAH
| FY Jun 2026 | 0.73x |
| FY Jun 2025 | 0.30x |
| FY Jun 2024 | 0.81x |
| FY Jun 2023 | 0.73x |
| FY Jun 2022 | 0.67x |
| Dec 2025 | 0.73x |
| Sep 2025 | 0.56x |
| Jun 2025 | 0.30x |
| Mar 2025 | 0.41x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.38x |
| Jun 2024 | 0.81x |
| Mar 2024 | 0.54x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity CAH
| FY Jun 2026 | n/a |
| FY Jun 2025 | n/a |
| FY Jun 2024 | n/a |
| FY Jun 2023 | n/a |
| FY Jun 2022 | -173.4% |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
| Mar 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+3.2%
TTM net income over average of 2024-12-31 and 2025-12-31
Return on assets CAH
| FY Jun 2026 | +3.2% |
| FY Jun 2025 | +3.2% |
| FY Jun 2024 | +1.9% |
| FY Jun 2023 | n/a |
| FY Jun 2022 | -2.1% |
| Dec 2025 | +3.2% |
| Sep 2025 | +3.2% |
| Jun 2025 | +3.2% |
| Mar 2025 | +3.3% |
| Dec 2024 | +2.8% |
| Sep 2024 | +3.0% |
| Jun 2024 | +1.9% |
| Mar 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+88.1%
operating income after a 26.4% effective tax rate, over long-term debt only, 2025-12-31 plus average of 2024-12-31 and 2025-12-31 minus cash
Return on invested capital CAH
| FY Jun 2026 | +88.1% |
| FY Jun 2025 | +356.5% |
| FY Jun 2024 | n/a |
| FY Jun 2023 | n/a |
| FY Jun 2022 | n/a |
| Dec 2025 | +88.1% |
| Sep 2025 | +81.4% |
| Jun 2025 | +356.5% |
| Mar 2025 | +327.6% |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
| Mar 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+19.1%
operating income (EBIT proxy) over average of 2024-12-31 and 2025-12-31 minus current liabilities
Return on capital employed CAH
| FY Jun 2026 | +19.1% |
| FY Jun 2025 | +19.2% |
| FY Jun 2024 | +13.0% |
| FY Jun 2023 | n/a |
| FY Jun 2022 | -4.0% |
| Dec 2025 | +19.1% |
| Sep 2025 | +20.4% |
| Jun 2025 | +19.2% |
| Mar 2025 | +19.7% |
| Dec 2024 | +18.8% |
| Sep 2024 | +21.6% |
| Jun 2024 | +13.0% |
| Mar 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing CAH
| FY Jun 2026 | n/a |
| FY Jun 2025 | n/a |
| FY Jun 2024 | n/a |
| FY Jun 2023 | n/a |
| FY Jun 2022 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
| Mar 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$61.5B
market value at close 2026-10-23 on 2026-07-31 shares, plus long-term debt only, 2025-12-31, minus cash 2026-06-30
Enterprise value CAH
| FY Jun 2026 | $59.4B |
| FY Jun 2025 | $44.2B |
| FY Jun 2024 | $23.5B |
| FY Jun 2023 | $23.9B |
| FY Jun 2022 | $14.3B |
| Dec 2025 | $54.4B |
| Sep 2025 | $41.9B |
| Jun 2025 | $44.2B |
| Mar 2025 | $37.1B |
| Dec 2024 | $31.9B |
| Sep 2024 | $28.3B |
| Jun 2024 | $23.5B |
| Mar 2024 | $28.2B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+9.5%
TTM free cash flow over market value at close 2026-10-23
FCF yield CAH
| FY Jun 2026 | +9.8% |
| FY Jun 2025 | +4.6% |
| FY Jun 2024 | +13.6% |
| FY Jun 2023 | +9.8% |
| FY Jun 2022 | +19.6% |
| Dec 2025 | +11.3% |
| Sep 2025 | +11.9% |
| Jun 2025 | +4.6% |
| Mar 2025 | +7.3% |
| Dec 2024 | -1.7% |
| Sep 2024 | +4.0% |
| Jun 2024 | +13.6% |
| Mar 2024 | +7.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing CAH
| FY Jun 2026 | n/a |
| FY Jun 2025 | n/a |
| FY Jun 2024 | n/a |
| FY Jun 2023 | n/a |
| FY Jun 2022 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
| Mar 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-06 | 2025-06 | 2024-06 | 2023-06 | |
|---|---|---|---|---|
| Revenue | $254.2B | $222.6B | $226.8B | $205.0B |
| Gross profit | $9.8B | $8.2B | $7.4B | $6.9B |
| Operating income | $2.6B | $2.3B | $1.2B | $752.0M |
| Net income | $1.7B | $1.6B | $852.0M | $330.0M |
| EPS (diluted) | 7.23 | 6.45 | 3.45 | 1.26 |
| Operating cash flow | $5.2B | $2.4B | $3.8B | $2.8B |
| Cash | $4.9B | $3.9B | $5.1B | $4.1B |
| Long-term debt | $7.0B | $8.0B | $4.7B | $3.9B |
| Buybacks | $1.4B | $765.0M | $750.0M | $2.0B |
| Dividends paid | $491.0M | $494.0M | $499.0M | $525.0M |
SEC XBRL, fiscal years, as known on 2026-10-27
CAH Stock Sonar score 6/7 axes
Find similar shapesCompareCAH ranks highest on growth (81st percentile) and profitability (78th), and lowest on insider conviction (3rd), among Wholesale & Retail peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CAH filings, in plain words
Are Cardinal Health insiders buying or selling CAH?
In the 180 days to 2026-10-27, Cardinal Health insiders were net sellers, a net $59.6M across purchases and sales reported on Form 4, by 7 sellers.
Have members of Congress traded CAH?
Yes, but not in the year to 2026-10-27; the latest on record is a purchase by Marjorie Taylor Greene dated 2025-10-24.
Are there planned insider sales of CAH?
Yes. 7 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $59.5M of stock; the latest, by Mary Scherer, was filed 2026-08-19.
Read the full summary
In the 180 days to 2026-10-27, Cardinal Health insiders were net sellers of CAH, a net $59.6M across purchases and sales reported on Form 4 by 7 sellers. None of the 31 insider sales was flagged as made under a Rule 10b5-1 plan. Members of Congress have disclosed trades in CAH, none in the last year; the latest on record is a purchase by Marjorie Taylor Greene dated 2025-10-24. Insiders filed 7 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $59.5M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
